Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer

Chris Armstrong, Oksana Lyubomska, Melissa J. LaBonte , David J. J. Waugh

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review


Cancer studies have entered an era that is heavily focused on the contribution of the tumor microenvironment. For this reason, in vivo experimentation in an immunodeficient model system is no longer fit for purpose. As a consequence, numerous genetically engineered mouse models (GEMMs) which self-develop tumors have been developed to allow experiments to be performed in a fully immunocompetent setting. One of the most commonly used technologies is Cre-loxP recombination due to its unique ability to control target gene expression in a specified tissue type. However, the major limitation of these models remains the inability to generate sufficient numbers of age-matched mice for a synchronized experimental start date. For this reason, the derivation of cell lines from genetically modified murine prostate tissue is desirable and allows for the generation of syngeneic models via subcutaneous or orthotopic injection.
Original languageEnglish
Title of host publicationProstate Cancer Methods and Protocols
PublisherHumana Press
Number of pages12
Publication statusPublished - 2018

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745


Dive into the research topics of 'Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer'. Together they form a unique fingerprint.

Cite this